{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:44:56Z","timestamp":1790019896342,"version":"4.0.1"},"reference-count":131,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001845","name":"Scleroderma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007253","name":"Nancy Taylor Foundation for Chronic Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001844","name":"Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rdc.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:15:07Z","timestamp":1630534507000},"page":"757-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma"],"prefix":"10.1016","volume":"47","author":[{"given":"Kathryn S.","family":"Torok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/acr.20070","article-title":"Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland","volume":"62","author":"Herrick","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2397198318763701","article-title":"Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from teh United States","volume":"3","author":"Beukelman","year":"2018","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib3","first-page":"2143","article-title":"Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. Multicenter Study Research Support, Non-U.S. Gov't","volume":"21","author":"Pelkonen","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib4","first-page":"1004","article-title":"Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't","volume":"33","author":"Scalapino","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib5","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1002\/art.22207","article-title":"Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database","volume":"54","author":"Martini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.07.004_bib6","article-title":"Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort. www.juvenile-scleroderma.com","author":"Foeldvari","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib7","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/acr.23547","article-title":"Clinical characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis: results from the childhood arthritis and rheumatology research alliance legacy registry","volume":"70","author":"Stevens","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.004_bib8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/rheumatology\/ker521","article-title":"Access to care for children and young people diagnosed with localized scleroderma or juvenile SSc in the UK. Comparative Study","volume":"51","author":"Hawley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2397198318790494","article-title":"Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort","volume":"4","author":"Foeldvari","year":"2018","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.rdc.2021.07.004_bib10","article-title":"Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points","volume":"101688","author":"Foeldvari","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"4","key":"10.1016\/j.rdc.2021.07.004_bib11","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/rheumatology\/keaa584","article-title":"Consensus-based recommendations for the management of juvenile systemic sclerosis","volume":"60","author":"Foeldvari","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib12","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3899\/jrheum.171362","article-title":"Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis","volume":"45","author":"Showalter","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.004_bib13","article-title":"Under detection of interstitial lung disease in juvenile systemic sclerosis (jSSc)","author":"Foeldvari","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2021.07.004_bib14","article-title":"Relationship between esophageal abnormalities on fluoroscopic esophagram and pulmonary function testing in juvenile systemic sclerosis","author":"Ambartsumyan","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib16","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fernandez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.004_bib18","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S","volume":"22","author":"Clements","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib20","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","article-title":"Improvement in skin thickening in systemic sclerosis associated with improved survival","volume":"44","author":"Steen","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.004_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24\u00a0week randomized double-blind trial, followed by a 24\u00a0week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib22","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A\u00a0randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Consensus Development Conference Research Support, Non-U.S. Gov't","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib24","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","article-title":"Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin","volume":"138","author":"Hinchcliff","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib26","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A\u00a0prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","volume":"48","author":"Derk","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib27","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3899\/jrheum.111229","article-title":"A\u00a0prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset","volume":"39","author":"Mendoza","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.004_bib29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"25","key":"10.1016\/j.rdc.2021.07.004_bib30","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.004_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib35","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kes041","article-title":"Articular involvement in systemic sclerosis","volume":"51","author":"Avouac","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.004_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 71","key":"10.1016\/j.rdc.2021.07.004_bib38","first-page":"S55","article-title":"Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis","volume":"30","author":"Omair","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.004_bib39","first-page":"1636","article-title":"Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease","volume":"34","author":"Lam","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib40","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Research Support, Non-U.S. Gov't","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(84)90986-0","article-title":"Factors predicting development of renal involvement in progressive systemic sclerosis","volume":"76","author":"Steen","year":"1984","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0025-6196(12)60418-2","article-title":"Use of captopril as early therapy for renal scleroderma: a prospective study","volume":"60","author":"Beckett","year":"1985","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib45","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.3899\/jrheum.100001","article-title":"Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort","volume":"37","author":"Foeldvari","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.004_bib46","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/rheumatology\/kes144","article-title":"Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database","volume":"51","author":"Foeldvari","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/art.1780240907","article-title":"Wide-field capillary microscopy. Research Support, Non-U.S. Gov't","volume":"24","author":"Maricq","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1759720X17740074","article-title":"Evidence-based management of Raynaud's phenomenon","volume":"9","author":"Herrick","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.23301","article-title":"Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients","volume":"58","author":"Goldman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib50","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6673","key":"10.1016\/j.rdc.2021.07.004_bib51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker","year":"1989","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.rdc.2021.07.004_bib52","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJM198304143081507","article-title":"Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon","volume":"308","author":"Rodeheffer","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.004_bib53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/ket417","article-title":"Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study","volume":"53","author":"Lee","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl S1","key":"10.1016\/j.rdc.2021.07.004_bib54","first-page":"227","article-title":"Phosphodiesterase-5 inhibitors: Raynaud's and beyond","volume":"12","author":"Phatak","year":"2017","journal-title":"Indian J Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.004_bib55","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.004_bib56","article-title":"Oral vasodilators for primary Raynaud's phenomenon","author":"Stewart","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib57","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib58","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib59","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2018.01.043","article-title":"A\u00a0systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon","volume":"78","author":"Curtiss","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib60","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/s10165-009-0199-4","article-title":"Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis","volume":"19","author":"Kuwana","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/000331978703800801","article-title":"Functional vascular disorders: treatment with pentoxifylline","volume":"38","author":"Neirotti","year":"1987","journal-title":"Angiology"},{"key":"10.1016\/j.rdc.2021.07.004_bib62","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"742","key":"10.1016\/j.rdc.2021.07.004_bib63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/pgmj.63.742.617","article-title":"Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis","volume":"63","author":"Rademaker","year":"1987","journal-title":"Postgrad Med J"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib64","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib65","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.07.004_bib67","first-page":"939","article-title":"Optimal management of digital ulcers in systemic sclerosis","volume":"11","author":"Abraham","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.004_bib68","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.004_bib69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/PL00011223","article-title":"Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years","volume":"21","author":"Bettoni","year":"2002","journal-title":"Clin Rheumatol"},{"issue":"8320","key":"10.1016\/j.rdc.2021.07.004_bib70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(83)91624-0","article-title":"Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial","volume":"1","author":"Belch","year":"1983","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib71","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3899\/jrheum.160592","article-title":"Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number, fingertip blood perfusion, and clinical status in systemic sclerosis","volume":"43","author":"Trombetta","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.004_bib72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/micr.1013","article-title":"Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: a description of treatment protocol and evaluation of results","volume":"21","author":"Tomaino","year":"2001","journal-title":"Microsurgery"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib73","first-page":"1286","article-title":"Digital sympathectomy for refractory Raynaud's phenomenon in an adolescent","volume":"19","author":"Drake","year":"1992","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib74","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","article-title":"A\u00a0prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma","volume":"39","author":"Uppal","year":"2014","journal-title":"J\u00a0Hand Surg Eur Vol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib75","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/micr.22379","article-title":"Surgical treatment of systemic sclerosis--is it justified to offer peripheral sympathectomy earlier in the disease process?","volume":"35","author":"Momeni","year":"2015","journal-title":"Microsurgery"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-018-1792-8","article-title":"Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study","volume":"21","author":"Del Papa","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib78","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1191\/0961203305lu2206oa","article-title":"Pulmonary arterial hypertension associated to connective tissue diseases","volume":"14","author":"Galie","year":"2005","journal-title":"Lupus"},{"issue":"127","key":"10.1016\/j.rdc.2021.07.004_bib79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rdc.2021.07.004_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib81","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/rheumatology\/ken388","article-title":"Factors affecting survival in juvenile systemic sclerosis","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.004_bib83","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib84","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib85","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease","volume":"63","author":"Roth","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib86","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib87","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","article-title":"Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis","volume":"18","author":"Shenoy","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib89","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/1756-185X.12399","article-title":"Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series","volume":"17","author":"Yilmaz","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib90","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"Berezne","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"22","key":"10.1016\/j.rdc.2021.07.004_bib91","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.rdc.2021.07.004_bib92","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib93","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, Phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.004_bib94","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","article-title":"Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy","volume":"40","author":"Keir","year":"2012","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib95","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/rheumatology\/keaa193","article-title":"Rituximab for rapidly progressive juvenile systemic sclerosis","volume":"59","author":"Zulian","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib96","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B\u00a0cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib98","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib99","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A\u00a0multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 113","key":"10.1016\/j.rdc.2021.07.004_bib100","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.004_bib101","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"10.1016\/j.rdc.2021.07.004_bib102","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"9790","key":"10.1016\/j.rdc.2021.07.004_bib103","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.004_bib104","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJMc1801275","article-title":"Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib105","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.39021","article-title":"Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.004_bib106","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib107","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung transplant in patients with scleroderma compared with pulmonary fibrosis. short- and long-term outcomes","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.004_bib108","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/1529-0131(199904)42:4<807::AID-ANR26>3.0.CO;2-T","article-title":"Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Case Reports Research Support, Non-U.S. Gov't","volume":"42","author":"Martini","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.004_bib109","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11926-000-0069-8","article-title":"Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease","volume":"2","author":"Wulffraat","year":"2000","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 9","key":"10.1016\/j.rdc.2021.07.004_bib110","first-page":"1538","article-title":"Efficacy and safety of autologous peripheral stem cell transplantation in three children with systemic sclerosis and progressive pulmonary involvement","volume":"43","author":"Martini","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.rdc.2021.07.004_bib112","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1001\/jama.2014.12572","article-title":"Cardiac assessment before stem cell transplantation for systemic sclerosis--reply","volume":"312","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.rdc.2021.07.004_bib113","first-page":"4547","article-title":"Breathing training on lower esophageal sphincter as a complementary treatment of gastroesophageal reflux disease (GERD): a systematic review","volume":"20","author":"Casale","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib114","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1164\/rccm.201309-1634ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation","volume":"188","author":"Spruit","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2 Suppl 65","key":"10.1016\/j.rdc.2021.07.004_bib115","first-page":"S26","article-title":"Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis","volume":"29","author":"Yuen","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib116","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/09638280903171527","article-title":"Oral hygiene in scleroderma: the effectiveness of a multi-disciplinary intervention program","volume":"32","author":"Poole","year":"2010","journal-title":"Disabil Rehabil"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib117","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s40674-014-0005-0","article-title":"Management of gastrointestinal involvement in scleroderma","volume":"1","author":"Nagaraja","year":"2015","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"3 Suppl 54","key":"10.1016\/j.rdc.2021.07.004_bib118","first-page":"5","article-title":"Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Randomized Controlled Trial Research Support, Non-U.S. Gov't","volume":"27","author":"Pakozdi","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.004_bib119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00004836-200208000-00001","article-title":"A\u00a0review of endoscopic methods of esophageal dilation","volume":"35","author":"Lew","year":"2002","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.004_bib120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/art.1780200105","article-title":"Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS","volume":"20","author":"Ramirez-Mata","year":"1977","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib121","first-page":"685","article-title":"Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities","volume":"23","author":"Mercado","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.004_bib122","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.1987.00370090075014","article-title":"Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities","volume":"147","author":"Johnson","year":"1987","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib123","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1572-0241.2007.01758.x","article-title":"Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication","volume":"103","author":"Parodi","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.004_bib124","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kep226","article-title":"Small intestinal bacterial overgrowth in systemic sclerosis","volume":"48","author":"Marie","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.004_bib125","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","article-title":"Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth","volume":"38","author":"Shah","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"2 Suppl 65","key":"10.1016\/j.rdc.2021.07.004_bib126","first-page":"S22","article-title":"Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating\/distention","volume":"29","author":"Frech","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.004_bib127","first-page":"905","article-title":"[Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma]","volume":"35","author":"Folwaczny","year":"1997","journal-title":"Z\u00a0Gastroenterol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.004_bib128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RHU.0b013e3180645d2a","article-title":"Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients","volume":"13","author":"Nikou","year":"2007","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.004_bib129","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/gut.51.6.881","article-title":"Sacral nerve stimulation for faecal incontinence due to systemic sclerosis","volume":"51","author":"Kenefick","year":"2002","journal-title":"Gut"},{"issue":"2 Suppl 58","key":"10.1016\/j.rdc.2021.07.004_bib130","first-page":"S42","article-title":"Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel","volume":"28","author":"Baron","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.004_bib131","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.40395","article-title":"The childhood arthritis and rheumatology research alliance consensus treatment plans: toward comparative effectiveness in the pediatric rheumatic diseases","volume":"70","author":"Ringold","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2101098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2101098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:21:56Z","timestamp":1760181716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X2101098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0889857X2101098X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}